Is PNC-27 safe for dogs?
The short answer
There is no honest way to characterise PNC-27 as safe or unsafe for dogs, because no dog has been formally studied. All published evidence is in vitro and rodent. The mechanism is genuinely interesting and the preclinical selectivity data is real, but the gap between that and a canine safety profile is enormous. This belongs in the hands of a veterinary oncologist making a considered decision about a specific patient, not in a general protocol.
The critical risks
⚠ No companion animal data exists
Every published finding on PNC-27 comes from cell culture or rodent models. There are no canine trials, no canine pharmacokinetics, and no canine safety data. This compound is included for completeness of the research landscape, not as a recommendation. It should only ever be considered under direct veterinary oncology supervision.
What the evidence base actually is
Safety claims are only as good as the studies behind them.
PNC-27 is a fragment derived from the p53 tumour suppressor protein. Laboratory research reports that it binds a protein called HDM-2 that sits on the surface of many cancer cells but not on healthy ones, and that this binding forms pores that rupture the cell. That selectivity is the appeal. It is important to be clear that this work is in cell culture and rodents — no dog has been formally studied.
Dosing context
Safety is dose-dependent. These are the figures reported in the source literature.
| Weight class | Reported dose | Frequency | Duration | Studied for |
|---|---|---|---|---|
| Small / toy breedunder 22 lb (10 kg) | 5-20 mg per dose | 2-3x weekly | 8-12+ weeks | Investigational oncology adjunct, veterinary supervision required |
| Medium breed22–77 lb (10–35 kg) | 10-70 mg per dose | 2-3x weekly | 8-12+ weeks | Investigational oncology adjunct, veterinary supervision required |
| Large / giant breedover 77 lb (35 kg) | 20-150 mg per dose | 2-3x weekly | 8-12+ weeks | Investigational oncology adjunct, veterinary supervision required |
See the full PNC-27 profile for mechanism, protocol and monitoring detail.
Common questions
Is PNC-27 safe for dogs?+
There is no honest way to characterise PNC-27 as safe or unsafe for dogs, because no dog has been formally studied. All published evidence is in vitro and rodent. The mechanism is genuinely interesting and the preclinical selectivity data is real, but the gap between that and a canine safety profile is enormous. This belongs in the hands of a veterinary oncologist making a considered decision about a specific patient, not in a general protocol.
What are the side effects of PNC-27 in dogs?+
No companion animal data exists: Every published finding on PNC-27 comes from cell culture or rodent models. There are no canine trials, no canine pharmacokinetics, and no canine safety data. This compound is included for completeness of the research landscape, not as a recommendation. It should only ever be considered under direct veterinary oncology supervision.
Can PNC-27 be given to a dog with cancer?+
PNC-27 is among the compounds investigated as an adjunct in canine oncology rather than being contraindicated in it. That said, the evidence is investigational and this belongs entirely in the hands of a veterinary oncologist managing the specific case.
Does my dog need testing before starting PNC-27?+
No compound-specific genetic testing is established for PNC-27. Baseline bloodwork before starting, and repeat testing during a protocol, is standard practice and lets your veterinarian catch a problem before it becomes clinically apparent.
References
- 1.Sarafraz-Yazdi E, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. PNAS, 2010. PMID 20080606
- 2.Sookraj KA, et al. The anti-cancer peptide PNC-27 induces tumor cell lysis as the intact peptide. Cancer Chemotherapy and Pharmacology, 2010. PMID 20182728
- 3.Davitt K, et al. The anti-cancer peptide PNC-27 induces necrosis in K562 leukemia cells. Annals of Clinical and Laboratory Science, 2014. PMID 25117093
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.